Senvion S.A.

  • WKN: A2AFKW
  • ISIN: LU1377527517
  • Land: Großherzogtum Luxemburg

Nachricht vom 03.01.2018 | 15:38

Senvion S.A.: Senvion closes Calendar Year 2017 with firm order intake of EUR 1,776 million (2016: EUR 1,304 million)

Senvion S.A. / Key word(s): Incoming Orders
Senvion S.A.: Senvion closes Calendar Year 2017 with firm order intake of EUR 1,776 million (2016: EUR 1,304 million)

03-Jan-2018 / 15:38 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Disclosure of an inside information acc. to Article 17 of the EU Market Abuse Regulation (EU 596/2014, MAR), transmitted by DGAP - The issuer is solely responsible for the content of this announcement.

Senvion closes Calendar Year 2017 with firm order intake of EUR 1,776 million (2016: EUR 1,304 million)

 

Luxembourg, 3rd Jan, 2017: Senvion determined today its firm order intake for the Calendar Year 2017. Senvion has closed the year with a firm order intake of EUR 1.776 billion in Calendar Year 2017, v/s order intake guidance of approx. EUR 2.0 billion, as two key order conversions have been delayed and shifted into early 2018. This risk of potential delays in converting orders is not unusual in a project driven business like Senvion and was already highlighted in our third quarter release. It is also pertinent to note that these delayed orders are already signed orders and accounted for in the conditional order book at the year end.

In 2017 Senvion S.A. achieved a firm order intake of EUR 1.776 billion (2016: EUR 1.304 billion), a year-on-year growth of more than 36%. This growth was mainly driven by new markets (Australia, South America, others) with firm order intake of EUR 685 million in 2017 (2016: EUR 145 million) and by offshore business with a firm order intake of EUR 306 million in 2017 (2016: EUR 0.0 million). Current markets witnessed a slowdown in order intake with firm order intake in Germany amounting to EUR 383 million in 2017 (2016: EUR 479 million).

Firm order intake is defined as the value of the contractually agreed orders which are not subject to further conditions.

Senvion Investor Relations contact (Notifiying Person):
Anja Siehler
Senior Manager - Capital Markets
phone: +352 26 00 - 5285
email: anja.siehler@senvion.com

About Senvion:
Senvion is a leading global manufacturer of onshore and offshore wind turbines. The company develops, produces and markets wind turbines for almost any location - with rated outputs of 2 MW to 6.33 MW and rotor diameters of 82 metres to 152 metres. Furthermore, the company offers its customers project specific solutions in the areas of turnkey, service and maintenance, transport and installation, as well as foundation planning and construction. The Senvion systems are mainly designed in the major TechCenters in Osterrönfeld and Bangalore and manufactured at its German and Portuguese plants in Bremerhaven, Vagos and Oliveira de Frades as well as in Żory-Warszowice, Poland and Baramati, India. With approximately 4,500 employees worldwide, the company makes use of the experience gained from the manufacture and installation of more than 7,500 wind turbines around the world. The company's operational subsidiary Senvion GmbH is based in Hamburg and represented by distribution partners, subsidiaries and participations in European markets such as France, Belgium, the Netherlands, the UK, Italy, Romania, Portugal, Sweden, and Poland as well as on a global level in the USA, China, Australia, Japan, India, Chile and Canada. Senvion S.A. is listed on the Prime Standard of the Frankfurt Stock Exchange.


03-Jan-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Hohes Kurspotenzial: „Attraktiver „Value-add“-Immobilienspezialist

Die Coreo AG führt derzeit eine Bezugsrechtskapitalerhöhung durch, in deren Rahmen ein Bruttoemissionserlös von bis zu 16 Mio. € angestrebt wird. Der Liquiditätserlös soll zum Erwerb von Gewerbe- und Wohnimmobilien für den Geschäftsbereich „Value Add“ verwendet werden. Derzeit, also pre money, verfügt die Gesellschaft über ein prognostiziertes NAV (auf Grundlage von GBC-Berechnungen) von 2,40 €. Für das laufende und kommende Geschäftsjahr rechnen wir mit einem spürbaren Ertrags- und Ergebnisanstieg. Neben der Steigerung von Mieterträgen sollte die Gesellschaft im nennenswerten Umfang Veräußerungserlöse erzielen sowie stille Reserven aufdecken. Auf Basis unseres DCF-Bewertungsmodells (post money) haben wir ein Kursziel von 3,10 € ermittelt. Auf Basis des aktuellen Kurses sowie des Platzierungspreises im Rahmen der Kapitalerhöhung von 1,60 € je Aktie lautet unserer Einschätzung KAUFEN.“

News im Fokus

Linde plc: Linde plc Declares Dividend in Fourth Quarter 2018

10. Dezember 2018, 12:31

Aktueller Webcast

Douglas GmbH

FY 2017/18 financial results

11. Dezember 2018

Aktuelle Research-Studie

Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Kaufen Pharming Group NV

12. Dezember 2018